Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability? - Takeaways - MDSpire
Feature

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies

  • May 6, 2026

  • 1 min

Share

  • 1

    - Focus on manufacturing and scalability in cell and gene therapy. - Insights shared from industry experts at Meeting on the Mesa. - Emphasizes the translation of innovation into real-world healthcare impacts. - Collaboration produced with IBTV. - Highlights challenges and opportunities in life sciences. - Video format captures real-time perspectives. - Aims to improve patient outcomes through advanced therapies.

Original Source(s)

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

  • May 6, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...